Thermoreversible gel for delivery of activin receptor-like kinase 5 inhibitor SB-505124 for glaucoma filtration surgery

Pharmaceutical Development and Technology

Volumn 18, Issue 4, 2013, Pages 957-962

  Sutariya, Vijaykumar ^a   Miladore, Nicholas ^a   Geldenhuys, Werner ^a   Bhatia, Deepak ^a   Wehrung, Daniel ^a   Nakamura, Hiroshi ^a,b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b SUMMA HEALTH SYSTEM   (United States)

Author keywords

ALK 5 inhibitor; Glaucoma filtration surgery; Pluronic F 127; Thermoreversible gel

Indexed keywords

POLOXAMER; PROTEIN SERINE THREONINE KINASE INHIBITOR; SB 505124; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; CORNEA CELL; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; EXPERIMENTAL RABBIT; FIBROBLAST; FIBROBLAST CULTURE; FILTERING OPERATION; GEL; GLAUCOMA; IN VITRO STUDY; IN VIVO STUDY; LOW TEMPERATURE; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; VISCOSITY;

ANIMALS; BENZODIOXOLES; BODY TEMPERATURE; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FIBROBLASTS; FILTERING SURGERY; GELS; GLAUCOMA; IMIDAZOLES; POLOXAMER; PROTEIN-SERINE-THREONINE KINASES; PYRIDINES; RABBITS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TEMPERATURE; TIME FACTORS; VISCOSITY;

EID: 84877868616     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2011.647035     Document Type: Article

References (26)

1. Addicks EM, Quigley HA, Green WR, Robin AL. Histologic characteristics of filtering blebs in glaucomatous eyes. Arch Ophthalmol 1983;101:795-798.
2. Gorovoy M, Koga T, Shen X, Jia Z, Yue BY, Voyno-Yasenetskaya T. Downregulation of LIM kinase 1 suppresses ocular inflammation and fibrosis. Mol Vis 2008;14:1951-1959.
3. Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C et al. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol 2002;62:58-64.
4. Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R et al. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 2004;64:7954-7961.
5. Sapitro J, Dunmire JJ, Scott SE, Sutariya V, Geldenhuys WJ, Hewit M et al. Suppression of transforming growth factor-ß effects in rabbit subconjunctival fibroblasts by activin receptor-like kinase 5 inhibitor. Mol Vis 2010;16:1880-1892.
6. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:1286-1292.
7. Cordeiro MF. Role of transforming growth factor beta in conjunctival scarring. Clin Sci 2003;104:181-187.
8. Jampel HD, Roche N, Stark WJ, Roberts AB. Transforming growth factor-beta in human aqueous humor. Curr Eye Res 1990; 9:963-969.
9. Saika S, Yamanaka O, Baba Y, Kawashima Y, Shirai K, Miyamoto T et al. Accumulation of latent transforming growth factor-beta binding protein-1 and TGF beta 1 in extracellular matrix of filtering bleb and of cultured human subconjunctival fibroblasts. Graefes Arch Clin Exp Ophthalmol 2001;239:234-241.
10. Lee DA. Drug delivery device. United StatesPatent No. 4863457, 1989.
11. Prata JA Jr, Minckler DS, Mermoud A, Baerveldt G. Effects of intraoperative mitomycin-C on the function of Baerveldt glaucoma drainage implants in rabbits. J Glaucoma 1996;5:29-38.
12. Wang ZY, Stern IJ. Disposition in rats of a polyoxypropylenepolyoxyethylene copolymer used in plasma fractionation. Drug Metab Dispos 1975;3:536-542.
13. Lee SH, Lee JE, Baek WY, Lim JO. Regional delivery of vancomycin using pluronic F-127 to inhibit methicillin resistant Staphylococcus aureus (MRSA) growth in chronic otitis media in vitro and in vivo. J Control Release 2004;96:1-7.
14. Johnston TP, Miller SC. Toxicological evaluation of poloxamer vehicles for intramuscular use. J Parenter Sci Technol 1985; 39:83-89.
15. Henry RL, Schmolka IR. Burn wound covering and the use of poloxamer preparations. Crit Rev Biocompatibility 1989;5:207-220.
16. Garcia Sagrado F, Guzman M, Molpereces J, Aberturas MR. Pluronic copolymers-characteristics properties and pharmaceutical applications: part II. Pharm Technol Europe 1994;38-44.
17. Miller S, Donovan M. Effect of Poloxamer 407 gel on the miotic activity of pilocarpine nitrate in rabbits. Int J Pharm 1982; 12:147-152.
18. Saettone MF, Giannaccini B, Delmonte G, Campigli V, Tota G, La Marca F. Solubilization of tropicamide by poloxamers: physicochemical data and activity data in rabbits and humans. Int J Pharm 1988;43(1-2):67-76.
19. Desai SD, Blanchard J. Evaluation of pluronic F127-based sustained-release ocular delivery systems for pilocarpine using the albino rabbit eye model. J Pharm Sci 1998;87: 1190-1195.
20. Lemp MA. Artificial tear solutions. Int Ophthalmol Clin 1973;13: 221-229.
21. Habib FS, Attia MA. Comparative study of the ocular activity in rabbit eyes of adrenaline bitartrate formulated carbopol and poloxamers gels. Arch Pharm Chem Sci 1984;12:91-96.
22. Lin HR, Sung KC. Carbopol/pluronic phase change solutions for ophthalmic drug delivery. J Control Release 2000;69:379-388.
23. Edsman K, Carlfors J, Petersson R. Rheological evaluation of poloxamer as an in situ gel for ophthalmic use. Eur J Pharm Sci 1998;6:105-112.
24. Majithiya RJ, Ghosh PK, Umrethia ML, Murthy RS. Thermoreversiblemucoadhesive gel for nasal delivery of sumatriptan. AAPS PharmSciTech 2006;7:67.
25. Choi HG, Oh YK, Kim CK. In situ gelling and mucoadhesive liquid suppository containing acetaminophen: enhanced bioavailability. Int J Pharm 1998;165:23-32.
26. Gong CY, Shi S, Dong PW, Zheng XL, Fu SZ, Guo G, Yang JL, Wei YQ, Qian ZY. In vitro drug release behavior from a novel thermosensitive composite hydrogel based on Pluronic F127 and poly(ethylene glycol)-poly(ε- caprolactone)-poly(ethylene glycol) copolymer. BMC Biotechnology 2009;9:8. Available at http://www. biomedcentral.com/1472-6750/9/8